Table 1 Demographics, clinical characteristics and blood analyses of patients (n=20)
Variable | Baseline | Placebo treatment | Raloxifene treatment | df | t/Z value | P |
|---|---|---|---|---|---|---|
Age (years) | 36.5 (8.5) | |||||
Education (years) | 13.4 (2.1) | |||||
WAIS-III FSIQ | ||||||
Estimated full-scale IQ | 92.4 (10.0) | |||||
WTAR | ||||||
Estimated premorbid IQ | 104.0 (6.5) | |||||
Sex (M/F) | 12/8 | |||||
Race (total) | ||||||
Caucasian | 15 | |||||
Asian | 1 | |||||
Caucasian/Asian | 3 | |||||
Other | 1 | |||||
Handedness (right/left) | 19/1 | |||||
Diagnosis | ||||||
Schizophrenia | 14 | |||||
Schizoaffective | 6 | |||||
Age of onset | 23.7 (6.3) | |||||
Illness duration | 12.9 (6.8) | |||||
Number of hospitalizations | ||||||
0–5 | 13 | |||||
>5 | 7 | |||||
Antipsychotic dose (CPZ equivalent) | 703.0 (590.0) | 699.0 (592.0) | 680.7 (574.7) | 19 | 1.34 | 0.18 |
% On prolactin-raising antipsychotics | 55% | |||||
Hormone assays | ||||||
Prolactin (mIU ml−1) | 619.8 (654.6) | 500.3 (457.7) | 484.2 (474.4) | 19 | 1.45 | 0.15 |
Luteinizing hormone | 5.2 (5.0) | 6.6 (6.8) | 5.1 (4.6) | 19 | <0.001 | 1.0 |
Follicle stimulating hormone | 9.2 (23.3) | 9.1 (22.9) | 9.8 (20.2) | 19 | 2.07 | 0.04 |
PANSS | ||||||
Positive | 14.5 (4.9) | 14.4 (5.7) | 13.4 (4.4) | 19 | 2.03 | 0.06 |
Negative | 14.8 (6.4) | 14.5 (4.7) | 14.1 (5.7) | 19 | 0.54 | 0.6 |
General | 30.7 (7.9) | 28.4 (6.6) | 28.5 (6.9) | 19 | 0.14 | 0.89 |
Total | 60.0 (16.6) | 57.3 (13.9) | 56.0 (13.8) | 19 | 0.76 | 0.46 |
Second-generation antipsychotics | ||||||
Olanzapine | 4 | |||||
Clozapine | 1 | |||||
Amisulpride | 2 | |||||
Risperidone | 2 | |||||
Aripiprazole | 1 | |||||
Ziprasidone | 1 | |||||
Quetiapine | 1 | |||||
Clozapine+paliperidone | 1 | |||||
Clozapine+amisulpride | 2 | |||||
Clozapine+aripiprazole | 1 | |||||
Clozapine+chlorpromazine | 1 | |||||
Risperidone+quetiapine fumerate | 1 | |||||
Second- and first-generation antipsychotics | ||||||
Clozapine+haloperidol | 1 | |||||
Zuclopenthixol+olanzipine | 1 | |||||
